学术探索
学术期刊
新闻热点
数据分析
智能评审

Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy

被引：44
作者：
Sone, H
Kawakami, Y
Kumagai, AK
Oduka, Y
Sekine, Y
Honmura, S
Segawa, T
Suzuki, H
Yamashita, K
Yamada, N
机构：
[1] Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan
[2] Univ Tsukuba, Inst Clin Med, Dept Ophthalmol, Tsukuba, Ibaraki 3058575, Japan
[3] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA
[4] Toagosei Co Ltd, Tsukuba Res Lab, Biosci Res Dept, Tsukuba, Ibaraki, Japan
来源：
LIFE SCIENCES | 1999年 / 65卷 / 24期
关键词：
vascular endothelial growth factor; vascular permeability factor; neutralizing/blocking antibody; neovascularization; proliferative retinopathy; oxygen-induced retinopathy; intraocular administration; animal retinopathy model;
D O I：
10.1016/S0024-3205(99)00526-3
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Vascular endothelial growth factor (VEGF), the strongest known angiogenic cytokine and also a potent enhancer of vascular permeability, is closely associated with diabetic ocular complications and other intraocular neovascular diseases. The therapeutic effect of VEGF-neutralizing antibody on oxygen-induced retinopathy in an experimental murine model of proliferative retinopathy was investigated. Intraocular and systemic injection of the antibody resulted in 46% and 18% reductions in the number of nuclei of newly formed vessels of this model, respectively. The results demonstrated that a neutralizing antibody against VEGF was highly effective in the treatment of intraocular neovascularization and suggested possible modes of therapy in human intraocular neovascular diseases, including diabetic proliferative retinopathy.
引用
收藏
页码：2573 / 2580
页数：8
相关论文
共 23 条
[1]   INCREASED VASCULAR ENDOTHELIAL GROWTH-FACTOR LEVELS IN THE VITREOUS OF EYES WITH PROLIFERATIVE DIABETIC-RETINOPATHY [J].
ADAMIS, AP ;
MILLER, JW ;
BERNAL, MT ;
DAMICO, DJ ;
FOLKMAN, J ;
YEO, TK ;
YEO, KT .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 118 (04) :445-450
[2]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[3]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[4]   SHEDDING LIGHT ON BLINDNESS [J].
BARINAGA, M .
SCIENCE, 1995, 267 (5197) :452-453
[5]  
CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317
[6]   Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy [J].
Donahue, ML ;
Phelps, DL ;
Watkins, RH ;
LoMonaco, MB ;
Horowitz, S .
CURRENT EYE RESEARCH, 1996, 15 (02) :175-184
[7]   Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat [J].
Dorey, CK ;
Aouididi, S ;
Reynaud, X ;
Dvorak, HF ;
Brown, LF .
ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (10) :1210-1217
[8]  
FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554
[9]   MOLECULAR AND BIOLOGICAL PROPERTIES OF THE VASCULAR ENDOTHELIAL GROWTH-FACTOR FAMILY OF PROTEINS [J].
FERRARA, N ;
HOUCK, K ;
JAKEMAN, L ;
LEUNG, DW .
ENDOCRINE REVIEWS, 1992, 13 (01) :18-32
[10]   SIGNIFICANCE OF VASCULAR ENDOTHELIAL GROWTH-FACTOR VASCULAR-PERMEABILITY FACTOR FOR SOLID TUMOR-GROWTH, AND ITS INHIBITION BY THE ANTIBODY [J].
KONDO, S ;
ASANO, M ;
SUZUKI, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 194 (03) :1234-1241
123